New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
11:00 EDTEBIX, CIEN, OREX, HSH, PAY, FIVE, NAV, ULTA, MONTOptions with decreasing implied volatility
Options with decreasing implied volatility: OREX IDIX MONT FIVE CIEN ULTA PAY EBIX NAV HSH
News For OREX;MONT;FIVE;CIEN;ULTA;PAY;EBIX;NAV;HSH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 3, 2015
11:01 EDTOREXOrexigen price target raised to $26 from $16 at Piper Jaffray
Subscribe for More Information
10:47 EDTOREXOrexigen Contrave data offer upside to expectations, says Leerink
Subscribe for More Information
10:42 EDTOREXOrexigen discloses patents with data on Contrave effect on CV outcomes
Orexigen disclosed in a regulatory filing that on March 3 the United States Patent and Trademark Office issued U.S. Patent No. 8,969,371 and made publicly available provisional patent applications to which the '371 Patent claims priority. The '371 Patent and the Provisional Patent Applications incorporate data from a pre-planned interim analysis of the large, randomized, placebo-controlled, cardiovascular, or CV, outcomes trial of Contrave, or the Light Study. The '371 Patent, which expires in 2034, is the first in the Light Study family of patent applications Orexigen has prosecuted and covers two subgroups of the larger Light Study patient population. The Provisional Patent Applications are part of the same family of patent applications that were first filed in December 2013. The '371 Patent and the Provisional Patent Applications contain claims related to a positive effect of Contrave on CV outcomes. The observed effects on CV outcomes were unexpected and appear to be unrelated to weight change, the company said. Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition "Importantly, the U.S. package insert for Contrave states that the effect of Contrave on CV morbidity and mortality has not been established," the company noted. For regulatory approval purposes, the Light Study included a pre-planned interim analysis designed to exclude a doubling of CV risk compared to placebo. This analysis was conducted based on 94 observed and adjudicated major adverse cardiovascular events, which was approximately 25% of the planned MACE for the Light Study. The 25% Interim Analysis was prospectively designed to enable an early and preliminary assessment of safety to support regulatory approval. A larger number of MACE are required to precisely determine the effect of Contrave on CV outcomes, Orexigen said.
09:26 EDTNAVOn The Fly: Pre-market Movers
Subscribe for More Information
08:37 EDTPAYVeriFone, Vantiv to benefit from Samsung Pay, says Pacific Crest
Subscribe for More Information
07:22 EDTNAVNavistar reports Q1 ends with $733M in manufacturing cash
Subscribe for More Information
07:22 EDTNAVNavistar sees Q2 adjusted EBITDA $100M-$150M
Sees Q2 manufacturing cash, cash equivalents and marketable securities between $700M-$800M. The company reiterated its forecast for retail deliveries of Class 6-8 trucks and buses in the United States and Canada to be in the range of 350,000 to 380,000 units for fiscal year 2015. It also announced that it remains on track to achieve its goal of an 8-10 percent adjusted EBITDA margin run rate exiting fiscal year 2015.
07:21 EDTNAVNavistar reports Q1 EPS (52c), consensus ($1.09)
Subscribe for More Information
February 27, 2015
08:11 EDTCIENCiena March weekly volatility elevated into Q1 and outlook
Ciena March weekly call option implied volatility is at 76, April is at 49, July is at 40; compared to its 26-week average of 43 according to Track Data, suggesting larger near term price movement into the expected release of Q1 results before the open on March 5.
February 26, 2015
08:21 EDTOREXOrexigen Contrave sales encouraging, says RBC Capital
Subscribe for More Information
07:22 EDTOREXOrexigen Contrave off to strong start, says JMP Securities
Subscribe for More Information
February 25, 2015
10:01 EDTFIVEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:35 EDTFIVEFive Below initiated with a Positive at Susquehanna
Target $39.
06:33 EDTOREXOrexigen reports Q4 EPS 0c, consensus 21c
Subscribe for More Information
February 24, 2015
09:03 EDTOREXUltragenyx adds Orexigen CEO to board
Ultragenyx Pharmaceutical (RARE) announced the appointment of Michael Narachi to the company's board, effective February 20. Narachi, President and CEO and a director of Orexigen Therapeutics (OREX), will serve as an independent director to Ultragenyx.
08:10 EDTOREXOrexigen resumed with an Outperform at Leerink
Target $8.
February 20, 2015
12:53 EDTNAVCitigroup sees truck carrier stocks poised to outperform
With the U.S. economy growing quickly, the stocks of truck carriers are likely to outperform the S&P 500, Citigroup believes. WHAT'S NEW: Truck transportation prices and truck carrier stocks "respond most directly to economic growth," Citigroup analyst Christian Wetherbee wrote in a note to investors today. After carriers' truckload rates rose 4% last year, the rates should rise by a similar amount this year, Wetherbee predicted. Economic growth, along with the difficulties the carriers are experiencing with recruiting drivers, should be supportive of additional rate increases, the analyst stated. Wetherbee warned that the stocks of truck builders usually underperform during periods such as the current one, when a large amounts of U.S. class 8 trucks are being built. Consequently, truck carrier stocks present investors with an opportunity, while investors should be cautious on truck builders and parts suppliers, he wrote. Among truck carriers, Swift (SWFT) is particularly attractive, since it has underperformed its peers over the last year, Wetherbee stated. Additionally, the company's results appear likely to at least meet consensus estimates, the analyst predicted. He also kept a Buy rating on another truck carrier, Knight Transportation (KNX) and maintained a Buy rating on Cummins (CMI), which builds truck engines. The analyst kept a Hold rating on truck builder PACCAR (PCAR). OTHERS TO WATCH: Navistar (NAV) builds trucks and Celadon (CGI) is another truck carrier. PRICE ACTION: In early afternoon trading, Swift rose 1%, Knight Transportation gained 1.3%, Cummins added 0.7%, and PACCAR lost 0.5%.
February 18, 2015
09:01 EDTCIENCiena names Marcus Starke as Chief Marketing Officer
Subscribe for More Information
February 17, 2015
17:06 EDTNAVIcahn gives quarterly update on stakes, takes new stake in Manitowoc
Subscribe for More Information
10:57 EDTEBIXEbix up 9% after report of London market tender win
Shares of Ebix are up 9% after Insurance Insider reported the company won the tender for developing a platform that will allow electronic placement to be introduced in London market. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use